Celyad Oncology SA
F:1C0

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
F:1C0
Watchlist
Price: 0.168 EUR 17.89%
Market Cap: 2m EUR

Operating Margin
Celyad Oncology SA

-3 457%
Current
-13 740%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 457%
=
Operating Profit
-6.4m
/
Revenue
186k

Operating Margin Across Competitors

No Stocks Found

Celyad Oncology SA
Glance View

Market Cap
2m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

1C0 Intrinsic Value
0.04 EUR
Overvaluation 76%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 457%
=
Operating Profit
-6.4m
/
Revenue
186k
What is the Operating Margin of Celyad Oncology SA?

Based on Celyad Oncology SA's most recent financial statements, the company has Operating Margin of -3 457%.

Back to Top